GlaxoSmithKline (GSK) and Theravance (THRX) say the new drug application for the once-daily...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

GlaxoSmithKline (GSK) and Theravance (THRX) say the new drug application for the once-daily investigational medicine FF/VI for patients with chronic obstructive pulmonary disease has been accepted by the FDA, indicating the application is sufficiently complete to permit a substantive review.